Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498316 · ClinicalTrials.gov registry record · Phase 1
Cord Blood Expansion on Mesenchymal Stem Cells
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT00498316: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00498316 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498316, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if combining cord blood units will be safe and result in the cells "taking" faster in recipients. The cord blood units will have their cell number increased in the lab using cells from a family member or they will be collected from an unrelated healthy donor.
Primary Outcome
Engraftment defined as a sustained ANC \> 0.5 x 109/L for 3 consecutive days and evidence of donor chimerism or autologous reconstitution by D+42
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Rituximab
- PROCEDURE Cord Blood Infusion
- OTHER ATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2007-07-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
What the finished NCT00498316 record still lists
NCT00498316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00498316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00498316 about?
NCT00498316 is a clinical study titled "Cord Blood Expansion on Mesenchymal Stem Cells". The goal of this clinical research study is to learn if combining cord blood units will be safe and result in the cells "taking" faster in recipients. The cord blood units will have their cell number increased in the lab using cells from a family member or they will be collected from an unrelated he...
What is the current status of trial NCT00498316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2007-07-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00498316?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Rituximab (DRUG), Cord Blood Infusion (PROCEDURE), ATG (OTHER).
Who is sponsoring clinical trial NCT00498316?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00498316's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI